Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Interest & Investment Income (2016 - 2019)

Historic Interest & Investment Income for Corcept Therapeutics (CORT) over the last 7 years, with Q1 2019 value amounting to $1.1 million.

  • Corcept Therapeutics' Interest & Investment Income rose 27312.93% to $1.1 million in Q1 2019 from the same period last year, while for Mar 2019 it was $3.5 million, marking a year-over-year increase of 63617.02%. This contributed to the annual value of $3.6 million for FY2022, which is 57240.08% up from last year.
  • According to the latest figures from Q1 2019, Corcept Therapeutics' Interest & Investment Income is $1.1 million, which was up 27312.93% from $1.0 million recorded in Q4 2018.
  • Corcept Therapeutics' Interest & Investment Income's 5-year high stood at $1.1 million during Q1 2019, with a 5-year trough of -$487000.0 in Q3 2016.
  • In the last 4 years, Corcept Therapeutics' Interest & Investment Income had a median value of $188000.0 in 2017 and averaged $255272.7.
  • Per our database at Business Quant, Corcept Therapeutics' Interest & Investment Income surged by 11765.91% in 2017 and then soared by 78255.81% in 2018.
  • Over the past 4 years, Corcept Therapeutics' Interest & Investment Income (Quarter) stood at -$410000.0 in 2016, then skyrocketed by 145.85% to $188000.0 in 2017, then surged by 454.26% to $1.0 million in 2018, then increased by 5.28% to $1.1 million in 2019.
  • Its last three reported values are $1.1 million in Q1 2019, $1.0 million for Q4 2018, and $759000.0 during Q3 2018.